psychopharmacology

Documents about psychopharmacology

• Major depressive disorder: From accurate diagnosis to effective treatment through first-person psychopharmacology#688748PhilArchive
• Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials#334350IRIS
• Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.#224736NCBI PubMed Central
• Essential Notes in Psychiatry#486878Directory of Open Access Books
• Memory experiences under psychedelics – an exploratory prospective online study#1040310OSF
• Therapeutic Drug Monitoring in Child and Adolescent Psychiatry#968798ClinicalTrials.gov
• Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review#359195Springer Nature OA
• Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.#247477NCBI PubMed Central
• Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis#359193Springer Nature OA
• Postpartum Depression and Anxiety: A Literature Review of Neural Mechanisms, Child Outcomes, and Treatment Outcomes#390052OSF
• Olanzapine in the Treatment of Patients With Anorexia Nervosa#848127ClinicalTrials.gov
• Schizophrenia Sensory Gating Deficit With Quetiapine#852956ClinicalTrials.gov
• The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia#313497Springer Nature OA
• Psychopharmacology and Brain Transforming Interventions: A Guide for Mental Health Professionals#393088ODU Digital Commons
• GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.#479206NCBI PubMed Central
• Koshering Psychedelics: Ayahuasca in the Ultra-Orthodox (Haredi) Jewish World#295827OSF
• Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence#462566Springer Nature OA
• Cannabis use influences the effect of episodic simulation on scene vividness and prosocial intentions#483864OSF
• Mapping narrative reports of drug induced experiences: A data-driven dictionary-based approach.#190351OSF
• Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic Factors#228797Springer Nature OA
• A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)#912794ClinicalTrials.gov
• Cannabis and Cannabinoid-Related Suspected Adverse Drug Reactions: Global Patterns and Cross-National Analysis Based on VigiBase^® Data#359196Springer Nature OA
• Low-dose cannabigerol (CBG) has different effects on sustained and divided attention in rats#416328OSF
• Ayahuasca rituals among ultra-Orthodox (Haredi) Jews: context, phenomenology, changes, and negotiations#455986OSF
• Mental Health Across the Care Continuum: A Review and Technology-Powered Reference Standard#236878OSF
• Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report#481883Dipòsit Digital de la Universitat de Barcelona
• Unbuckling the Chemical Straitjacket: The Legal Significance of Recent Advances in the Pharmacological Treatment of Psychosis#494573UC College of Law
• Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program#478589Europe PMC
• Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders#811973ClinicalTrials.gov
• Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials#680892Springer Nature OA
• Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”#186608OSF
• Methodological framework to identify possible adverse drug reactions using population-based administrative data [v1; ref status: indexed, http://f1000r.es/3ys]#20013DOAJ
• Prescription Trends for Bipolar Disorder With and Without Comorbid Substance Use and Anxiety Disorders: A Global Bipolar Cohort Collaborative Study#476058HAL (France)
• Evidence-based consensus guidelines for the pharmacological management of substance dependence: recommendations from the British Association for Psychopharmacology#331664Spiral
• Factor Structure and Symptom Profiles of the Montgomery–Åsberg Depression Rating Scale (MADRS): A Meta-Analytic Mean and Covariance Structure Analysis#355590OSF
• Towards a genetics of mental disorders as complex dynamical systems: A symptom-specific and symptom-interactive approach#976789OSF
• Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)#850688ClinicalTrials.gov